THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

Lobbying for THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 23, 2025

Expenses

$100,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Texas

Official filing document

Government bodies contacted 4

Food & Drug Administration (FDA)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 4

Medicare/Medicaid

All legislation related to Medicare site of service payment policy changes; the Cassidy Hassan Senate framework for hospital site neutral payments; Issues related to Medicare reimbursements for cancer services; Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage preauthorization; Medicare Advantage access issues; Cuts to services related to cancer diagnosis and treatment; Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products; Policies related to the value of cancer care and initiatives that bend the cost curve; Issue related to site neutral payment reforms being included in the OBBB

Budget/Appropriations

Issues related to the President's upcoming federal budget request; Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI. Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant recisions

Government Issues

Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; impact of executive order on NIH indirect costs and what it means for the institution and the biomedical research space as a whole; the future of ARPA-H; federal grant terminations; DOGE information website on grant recipients; the future of global health programs

Medical/Disease Research/Clinical Labs

Issues related to clinical trial design and patients obtaining drugs sooner in the course of the trial

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.